The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an open-label, randomized phase ii clinical trial

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 1060-1067

  Sebastian, Martin ^a   Reck, Martin ^b   Waller, Cornelius F ^c   Kortsik, Cornelius ^d   Frickhofen, Norbert ^e   Schuler, Martin ^f   Fritsch, Holger ^g   Gaschler Markefski, Birgit ^g   Hanft, Gertraud ^g   Munzert, Gerd ^g   Von Pawel, Joachim ^h  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d St Hildegardis Krankenhaus   (Germany)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h Asklepios Fachkliniken   (Germany)

Author keywords

BI 2536; Phase II; Plk 1 kinase inhibition; Stage IIIB IV NSCLC

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; PLACEBO; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; PATHOLOGY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77954423900     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d95dd4     Document Type: Article

References (28)

1. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004;5:27-36. (Pubitemid 38072557)
2. Yap TA, Molife LR, Blagden SP, et al. Targeting cell cycle kinases and kinesins in anticancer drug development. Expert Opin Drug Discov 2007;2:539-560. (Pubitemid 47073077)
3. Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-117.
4. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267-276. (Pubitemid 40188607)
5. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330.
6. Holtrich U, Wolf G, Brauninger A, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994;91:1736-1740. (Pubitemid 24080280)
7. Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14:543-549. (Pubitemid 27090956)
8. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-5794. (Pubitemid 36576886)
9. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-322. (Pubitemid 46241881)
10. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315. (Pubitemid 46251642)
11. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-848.
12. Mross K, Frost A, Steinbild S, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-5517.
13. Hofheinz R, Hochhaus A, Al-Batran S, et al. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumour. J Clin Oncol 2006;24:2038.
14. Munzert G, Steinbild S, Frost A, et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J Clin Oncol 2006;24:3069.
15. Ellis PM, Chu QS, Leighl NB, et al. A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008;26:8115.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
18. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16: 139-144. (Pubitemid 28041591)
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
20. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381. (Pubitemid 16163075)
21. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996;6:443-457.
22. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71. (Pubitemid 40081295)
23. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007;10:162-181. (Pubitemid 47449762)
24. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
25. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
26. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: 1589-1597. (Pubitemid 41079796)
27. Olmos D, Swanton C, de Bono J. Targeting polo-like kinase: learning too little too late? J Clin Oncol 2008;26:5497-5499.
28. Lee K-H, Schlenk RF, Bug G, et al. Polo-like kinase-1 (Plk-1) inhibitor BI 2536 induces mitotic arrest and apoptosis in vivo: first demonstration of target inhibition in the bone marrow of AML patients. Blood (ASH Annual Meeting Abstracts) 2008;112:2641.